Vevorisertib trihydrochloride salt form · hydrochloride · Parent Vevorisertib trihydrochloride · Synonyms: ARQ 751 trihydrochloride

Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors.

For research use only. Not for human or veterinary use.

Target Akt

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

Vevorisertib trihydrochloride structure

CAS No.: 1416775-08-0

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
50 mg	USD 485.00	BP-02268A-50mg	In stock	Get quote
100 mg	USD 685.00	BP-02268A-100mg	In stock	Get quote
200 mg	USD 985.00	BP-02268A-200mg	In stock	Get quote
500 mg	USD 1,550.00	BP-02268A-500mg	In stock	Get quote
1 g	USD 2,450.00	BP-02268A-1g	In stock	Get quote
5 g	Inquire	BP-02268A-5g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC50 values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively.

Biological activity

Identifiers

SMILES: CC(=O)N(C)C1CCN(CC1)C2=CC=CC(=C2)C3=NC4=C(C=C3)N=C(N4C5=CC=C(C=C5)C6(CCC6)N)C7=C(N=CC=C7)N.Cl.Cl.Cl
InChIKey: HNFNJTGXAZHZSB-UHFFFAOYSA-N

Specifications

MW (average): 696.1120
Formula: C₃₅H₄₁Cl₃N₈O
CAS No.: 1416775-08-0
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder 4℃, 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO/H2O

In vitro: DMSO : 100 mg/mL H2O : 25 mg/mL

Documents

References

[1]. Yu Y, et al. Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092. PLoS One. 2015 Oct 15;10(10):e0140479.

[2]. Kozinova M, et al. Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor. Cancers (Basel). 2021 Jul 23;13(15):3699.

Same target

Search Akt

Same research area

Search Cancer